The selling is modest in absolute terms and negligible relative to market cap. These appear to be routine, pre-planned transactions following stock option exercises rather than a signal of fundamental concern. Traders should monitor for any changes in forward-looking statements or corporate guidance, but no immediate reaction is warranted.
Price Chart
Executive Summary
Three United Therapeutics executives, including the CEO, CFO, and General Counsel, conducted open-market share sales totaling $459K over a 7-day period, following large non-cash derivative exercises. The sales represent less than 0.002% of the company's $25.4B market cap and appear to be part of pre-planned transactions following stock option exercises.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold $227K worth of shares (395 shares) across multiple days in the cluster window at prices between $569.78 and $575.29.
- CFO James Edgemond sold $298K worth of shares (520 shares) on April 16, following the exercise of 20,000 derivative securities at two different strike prices.
- EVP Paul Mahon sold $115K worth of shares (200 shares) on April 16, following the exercise of 16,600 derivative securities.
- Total open-market sales in the cluster: $459K, representing less than 0.002% of $25.4B market cap.
- Multiple non-cash derivative exercises occurred at $0 and at strike prices ($135.42, $146.03), indicating pre-scheduled option expirations or vesting events.
Financial Impact
$459,000 in open-market sales
Risk Factors
- Perception risk: Concentrated selling by top executives could be misinterpreted as lack of confidence, despite likely being mechanical.
- Execution risk: Future larger-scale sales could occur if more options are exercised and sold under Rule 10b5-1 plans.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1776459415868 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $571.38 (+14.20%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $571.38 (+14.94%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $571.38 (+13.40%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $571.38 (+12.74%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $571.38 (+17.18%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $571.38 (+17.05%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $571.38 (+10.85%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $571.38 (+8.23%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access